Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?
Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.
Pharma & Biotech
Medical Devices & Diagnostics
Natera just cleared a major European hurdle for Signatera, but can hospitals turn certification into adoption?
Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.
Pharma & Biotech
Why Natera’s latest Signatera study matters for resected metastatic colorectal cancer
Discover how Natera’s Signatera MRD test may sharpen chemotherapy decisions after colorectal liver surgery and what remains unproven.
Pharma & Biotech
Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial
See how Natera’s Signatera could sharpen APG-157’s Phase 3 evidence in head and neck cancer and what risks remain. Read the analysis.
Medical Devices & Diagnostics
Why Natera’s Diakonos Oncology collaboration matters for ctDNA-guided cancer drug development
Natera’s Signatera will track molecular response in a refractory melanoma trial. Find out why ctDNA is becoming central to oncology R&D.
Medical Devices & Diagnostics
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.
Pharma & Biotech
Can ctDNA-guided bladder preservation become viable after Signatera’s ASCO GU data?
New ASCO GU data shows how Signatera ctDNA may guide bladder preservation and adjuvant therapy decisions in muscle-invasive bladder cancer. Read the analysis.
Medical Devices & Diagnostics
Can personalized ctDNA finally solve the risk stratification gap in therapy-resistant early breast cancer?
New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.
Pharma & Biotech
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor